From June 15 to 17, 2023, the liver failure team led by Professor Zhao Yingren and Professor He Yingli from Department of Infectious Diseases of the First Affiliated Hospital (FAH) of Xi 'an Jiaotong University (XJTU) was invited to attend the 12th National Conference of the China Network for Severe Liver Diseases (CNSLD). At the conference, the team presented 6 latest research results on clinical treatment and mechanism of liver failure, which were highly recognized by the organizers of the conference including CNSLD and Beijing You'an Hospital affiliated to Capital Medical University. The influence of this discipline in the field of liver failure was further elevated.
The project entitled Clinical research of artificial liver for liver failure applied by doctoral student Yan Taotao from the liver failure team was supported by the Special Funding for Artificial Liver of Beijing IGANDAN Foundation. On behalf of the liver failure team, doctoral student Xu Lingyun reported the latest research results regarding the mechanism of endocytosis inhibitor-targeting endotoxin-autophagy-ZO-1 axis for improving intestinal barrier, which grabbed the first prize at the conference (only 5 awardees in China). At the conference, the team also shared multiple research outcomes covering long-term efficacy and safety of tenofovir dipivoxil in the treatment of HBV-ACLF (selected as excellent article in clinical research), nutritional evaluation and prediction related to liver failure, clinical application of mNGS in bacterial and fungal infections related to liver failure, and novel prognosis prediction and evaluation model for liver failure, respectively.
